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Summary This study presents a retrospectix-e resiew- of chest radiography in children with Murphy stage III
T-cell lI-mphoblastic lvmphoma. All receis-ed a standard leukaemia-based protocol with intensise induction.
consolidation and continuing chemotherapy. Neither initial thoracic disease bulk nor the presence of a pleural
effusion predicted outcome. How-ever a significant difference was found w-hen the 50 patients in whom the
chest radiograph returned to normal within 60 days of commencing treatment w-ere compared with the 18
patients with persistent mediastinal abnormalities. for both esent-free [hazard ratio < 60 days to >60 days
(HR) 3.55 (950o CI 1.33-9A48); P = 0.0071 and oserall survisal [HR 2.95 (950o CI 1.07-8.18): P = 0.03]. It
appears that this relatisely simple estimate of chemosensitivity may identify a group of particularly zood-risk
patients in whom drugs associated with late morbidity such as anthracy-clines may be reduced and converselv a
higher risk group in whom further intensification of treatment would be justified
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Despite a steady improvement in the results of treatment of
childhood T-cell I,mphoblastic lywmphoma over the past 20
vears, overall 30-4000 of patients still relapse. Ideally, one
would like to be able to predict which subgroup will have a
poor outcome either before treatment or shortly after stan-
dard therapy has started. Early recognition of these children
would allow the use of a more intensive treatment protocol
introducing different drugs and perhaps high-dose chemo-
therapy with bone marrow rescue. or addition of local treat-
ment such as mediastinal irradiation.
It is now established that T-cell lymphoblastic lymphoma
and T-cell acute l'mphoblastic leukaemia (T-ALL) are
different parts of a disease spectrum. the latter diagnosis
being defined arbitrarily when the bone marrow contains
more than 25°0o lymphoblasts. With the exception of
advanced stage at presentation. the use of patient characteris-
tics, cell markers. immunocv'tochemistr- and immunophen-
otyping have failed to provide a consistentlv reliable index of
poor prognosis (Crist et al.. 1988: Berger et al.. 1990: Pui et
al.. 1990: Shuster et al.. 1990). It remains possible that the
use of high resolution cytogenetics or molecular markers may
yet be able to define precise abnormalities which can be used
to select treatment regimens (Lange et al.. 1992).
The United Kingdom Children's Cancer Study Group
(UKCCSG) study 8503 in advanced stage childhood T-cell
ly'mphoblastic ly'mphoma (Eden et al.. 1992) is one of the
largest published using a single treatment protocol (Figure 1)
for this rare malignancy. In summary. it comprised treatment
induction with weekly intravenous (i.v.) vincristine for 4
weeks, daily oral prednisolone for 28 days. iv.% daunorubicin
on days 1 and 2. Erwinia L-asparaginase intramuscularly or
subcutaneously for a total of nine doses and intrathecal (i.t.)
methotrexate on days 1. 15 and 28. All patients received early
(week 5) and late (week 20) intensification modules consisting
of i.t. methotrexate and i.v. vincristine on dav 1, i.V.
daunorubicin on days I and 2. i.v. cytosine arabinoside 12
hourly on days 1-5 inclusive. i.v. etoposide on days 1-5
inclusive. oral 6-thioguanine on days 1-5 inclusive and oral
prednisolone for 7 days and tailing off by day 14 of
intensification. Drugs doses are given in Figure 1.
Following recovery of blood counts after early
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intensification. all patients receised standard treatment to the
central nervous sy-stem with cranial irradiation (18 Gy) in ten
fractions of 1.8 Gy over 2 weeks and three further weekly i.t.
methotrexate doses at the same time. During irradiation. oral
mercaptopurine was administered daily. Continuing treat-
ment between the two intensification modules and after the
second until 2 years has elapsed from when remission was
achieved was with daily mercaptopurine throughout and
once-weekly oral methotrexate wvith the addition of pred-
nisolone orally- for 5 days and a single i.v. vincristine injec-
tion every 4 weeks. All patients received oral cotrimoxazole
twice daily three times a week from the beginning of week 5
until the end of all continuous therapy.
In the present study. clinical measures of disease bulk at
presentation have been retrospectively collected on all the
Murphy stage III patients with centrally confirmed T-cell
ly'mphoblastic ly-mphoma. The objectives were to document
the time to clinical and radiological complete remission. the
relationship between complete remission and the presence of
a pleural effusion or 'white-out'. the bulk of initial disease.
the size of the mediastinal mass. mediastinal mass to thorax
ratio and nodal size at presentation. From these data it was
hoped to determine whether or not it is possible to select
prospectively which patients will do badly on pretreatment
clinical criteria and on response to treatment.
Methods
Registration data from the UKCCSG T-cell ly'mphoblastic
lymphoma study protocol 8503 were obtained. This provided
the patients' trial number. their first and surname. the centre
which entered and treated them. the date of diagnosis. their
clinical stage at presentation and the date they were last
reviewed along with their clinical status at that time. Of the
99 patients registered. 15 were excluded from this analysis as
being other than stage III (two with stage II and 13 with
stage IV disease).
Original histological reviesw had been undertaken centrally
by a panel of three pathologists who used the Kiel
classification system. Histology' reports on the stage III
patients recorded 78 patients with T-cell lymphoblastic ly-m-
phoma, five patients with large-cell anaplastic lymphoma and
one patient with pleomorphic T-cell non-Hodgkin's lym-
phoma (NHL). To ensure a homogeneous patient populationChidhood T-celly hOblastic lmhom
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Week 1 2 3 4 5 6
Bone marrow
Intrathecal methotrexate
Cranial radiotherapy
Asparaginase 6000 u m-2 s.c.
Vincristine 1.5 mg m-2 i.v.
Daunorubicin 45 mg m-2 i.v.
Prednisolone 40 mg/mr2 p.o.
Etoposide 100 mg m-2 i.v.
Cytarabine
100 mg m-2 i.v. 12 hourly
Thioguanine 80 mg m-2 p.o.
Mercaptopurine 75 mg m-2 p.o.
Methotrexate 20 mg m-2 p.o.
Co-trimoxazole p.o.
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Figre 1 Outline of UKCCSG 8503 regimen. There is a standard four-drug induction followed by two intensification blocks and
continuing chemotherapy up to a total of 2 years. Central nervous system-directed therapy is with intrathecal methotrexate and
cranial irradiation ( 18 Gy.).
only those with confirmed T-cell lymphoblastic lymphoma
were included in this analysis.
A clinical data sheet was compiled which detailed the
information required. Assessment of measurable disease was
requested on day 1. between days 2 and 27 when available as
assessment during this period was discretionary, on day 28 (a
standard reassessment time of the 8503 regimen) and subse-
quently. The data collected comprised details of the presence
or not of a pleural eff-usion, the size of any mediastinal mass
and whether this was associated with a radiological white-
out'. mass to thorax ratio and the size of any palpable
lymphadenopathy. The time in days from diagnosis and the
start of treatment to complete radiological remission as
determined by plain posteroanterior (PA) chest radiograph
(CXR) was recorded. Data were taken from the original
report by the radiologist, or if information was inadequate
the relevant CXRs were reviewed locally. Blind central review
was not performed. Computerised axial tomographic (CAT)
scanning of the thorax was used neither routinely during
initial staging nor to further assess residual mediastinal
masses. The same applied to gallium scanning. None of the
patients with persisting mediastinal abnormalities underwent
biopsies to try to confirm the presence or otherwise of
residual lymphoma. Lactate dehydrogenase levels were not
routinely estimated during initial staging.
A total of 18 centres throughout the United Kingdom were
contacted. Thirteen provided data through the post, while the
other five were visited and the relevant information extracted
from notes and radiographs.
For the purpose of event-free survival, patients with persis-
tent mediastinal abnormality were considered to be in a state
of relapse at 60 days. Survival is defined as time to death
from any cause. For surviving patients. survival is censored
at the date of last follow-up. Survival curves were construc-
ted by the Kaplan-Meier method, 95% confidence intervals
(CIs) being calculated from the asymptotic variance of log
[-log(survival fraction)J. Survival curves were compared
using the log-rank test, and where categories were ordered.
e.g. size of lymphadenopathy, a trend test was employed.
Hazard ratios (HRs) were calculated using Cox's regression
(BMDP program 2L).
Results
Clinical and radiological data were collected on all 78 stage
III patients with confirmed T-cell lymphoblastic lymphoma.
There was no statistically significant relationship between
survival and the size of mediastinal mass. the mass to thorax
ratio. a 'white-out', a pleural effusion. or lymph node disease
bulk at presentation (Table I). One patient was noted to have
hepatosplenomegaly and one other bulky renal disease.
Normalisation of a plain PA CXR was a measure of
clinical and radiological complete remission in all but two
patients. each of whom had presented with bulky lymph
node masses greater than 5cm in diameter. Both these
patients remain alive and disease free.
At the time of data analysis 60 patients remained alive and
well with no evidence of recurrent disease. one having been
successfully salvaged after relapse. Eighteen patients had
died. 14 from disease. two from infection and two from other
causes. Median follow-up of living patients was 70 months,
range 51-109 months.
One centre administered mediastinal irradiation routinely
at the same time as cranial prophylaxis. although this was
not part of the UKCCSG protocol. Seven patients were
treated to a mid-plane dose of 15 Gy in ten daily fractions of
1.5 Gy over 2 weeks and their mediastinal masses resolved
within 10-35 days. One patient subsequently relapsed in
bone marrow and died. The other six remain alive and well.
Although the mediastinal radiotherapy was given during
weeks 9 and 10 of the protocol, which was at least 25 days
after the resolution of the mediastinal masses of all the
recipients. these patients have been excluded from the event-
free and overall survival calculations. This ensured that the
analysis included only those patients who received uniform
treatment according to protocol.
Survival analyses were undertaken at 30. 60 and 90 days
from the start of treatment. When the outcome in the 50
children whose CXRs had normalised within 60 days was
compared with the outcome in the 18 in whom mediastinal
abnormality persisted beyond 60 days. both 5 year event-free
survival [84% (95% CI 71-92%) vs 56% (95% CI 31-75%);
HR 3.55 (95% CI 1.33-9.48); P = 0.007] and 5 year overall
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Table I Outcome in relation to initial radiological features
Nwnber of Survivors Five year survival (%)
Feature patients NED (95% CIJ P-value
Total 78 60
Mediastinal mass 73 55
No mass 5 5 100
Mass <10 cm 21 17 81 (57-92)
Mass > 10cm 33 23 70 (51-82) NS
White-out 19 15 79 (53-91)
Mass-thorax ratio < 33% 11 10 91 (51-99)
Mass-thorax ratio >33% 43 30 70 (54-81) NS
Effusion 43 35
No effusion 35 25 71 (53-83)
Unilateral 38 30 79 (62-89) NS
Bilateral 5 5 100
Lymphadenopath; 49 40
None 29 20 69 (49-82)
<2 cm 19 14 74 (48-88)
2-5cm 20 18 90 (66-97) NS
>5cm 10 8 80 (41-95)
survival [84% (95% CI 71-92%) vs 61% (95% CI 35-79%);
HR 2.95 (95% CI 1.07-8.18); P = 0.03] were significantly
better (Figures 2 and 3). There was almost no difference in
the outcome between 60 and 90 days as only one of the
patients who had not achieved a complete response (CR) by
60 days did so by day 90. The analysis at 30 days showed no
statistical difference in outcome between the two groups
(data not shown).
To see whether the 11 patients with a mass to thorax ratio
of .33% favourably influenced the outcome of the 60
day group. we repeated the event-free survival analysis using
only those patients with a mass to thorax ratio of > 33% or
with a white-out. The result remained significant [HR 3.65
(95% CI 1.02-13.02); P= 0.03].
In the group of long-term survivors, only 7 of the 60 had a
persistent mediastinal mass 2 months from the start of treat-
ment. Of the 14 patients who died from disease, in four an
abnormal mediastinum persisted until death (at 41, 8, 11, and
17 months from diagnosis), and in a fifth an effusion never
cleared before death 14 months after presentation. One other
patient who died from disease had an abnormal mediastinal
outline on PA CXR for over 5 months.
The pattern of disease at relapse and outcome in the
treatment failures are shown in Table II. Three out of seven
rapid and five out of eight slow responders failed at the
primary site of mediastinal bulk disease.
Dixssco
The UKCCSG T-cell NHL 8503 study used a uniform
chemotherapy protocol and cranial irradiation throughout its
duration, and included the majority of cases of childhood
T-cell lymphoblastic lymphoma in the United Kingdom
between 1985 and 1990. This study therefore provides an
opportunity to examine, in an unselected, homogeneous
population, clinical and radiological measures of disease at
presentation and to test for any relationship between such
measures, rapid initial treatment response and outcome.
The patients whose mediastinal masses resolved within 60
days of commencing chemotherapy have a significantly better
survival. The decision to analyse at 30, 60 and 90 days was
based on day 28 being a standard point of assessment in the
8503 protocol and our observation that the great majority of
rapid responders had achieved a radiological complete res-
ponse by 60 days. borne out by the 90 day result being
almost the same. It is possible that with a larger prospective
study a different cut-off might be obtained.
Early resolution of a mediastinal mass in this disease
reflects chemosensitivity and residual abnormalities are likely
to be due to persisting tumour, although thrombosis and
fibrosis have been documented. T-cell lymphoblastic lym-
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Figre 2 Event-free survival by response at 60 days. (
CR. n = 50 cases -. no CR. n = 18 cases). Difference is
significant (r = 7.20. d.f. = 1. P<0.01).
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Figue 3 Overall survival by response at 60 days. Survival in
relation to radiological complete response. Sixty-eight patients
were analysed. The seven patients who received mediastinal
irradiation and the two who died from infection before 60 days
had elapsed from commencing chemotherapy were excluded.
There was insufficient data on one patient to define radiological
response. (- , CR n =50 cases. . no CR n = 18 cases).
Difference is significant (X: = 4.76. d.f. = 1, P<0.05).
phoma is unlikely to have a significant stromal component,
which is a frequent cause of a residual mediastinal abnor-
mality in Hodgkin's disease (North et al. 1987; Sandrock et
al., 1992).
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Table n Site of relapse and outcome in relation to complete response (CR)
as indicated by chest radiography by day 60
CR 60 dais CR >60 dais (or never)
Relapsed and Bone marrow Ia
died CNS 1 1
Bone marrow + CNS 1
Mediastinum 3 5b
Testicular 1
Relapsed and CNS -
salvaged
Other deaths Right atrial thrombus 1
Radiation encephalopathy 1
Infection 2'
aExcluded from survival analysis as patient received mediastinal irradiation.
bProgression of mediastinal mass. cExcluded from survival analysis as died
within 60 days of starting treatment.
Using the persistence of an abnormal mediastinum on
plain PA CXR more than 60 days from the start of
chemotherapy, we have defined a significant prognostic factor
indicating a subgroup of patients who may benefit from
additional treatment. By using this simple measure of treat-
ment response, approximately 25% of children with T-cell
lymphoblastic lymphoma would appear to have a poorer
prognosis.
The majority of patients presenting with T-cell lymphob-
lastic lymphoma in childhood have stage II disease by virtue
of their mediastinal mass. In the absence of bone marrow,
central nervous system (CNS) and testicular involvement at
presentation. the most likely site of residual disease after
systemic chemotherapy is where initial disease was most
bulky. This was the commonest pattern of relapse or failure
observed, with eight patients suffering recurrent or persistent
mediastinal disease. Distant failure was experienced by seven
children and comprised one testicular, two marrow, three
CNS and one combined marrow and CNS.
There was no specified salvage therapy as part of the 8503
protocol, and the few patients who were salvaged relapsed
more than 2 years out from initial treatment and underwent
autologous bone marrow transplantation. This indicates the
need to consider intensive salvage regimens using marrow
transplant procedures to be part of future protocols, and
reinforces the message of treatment intensification for any
poor prognosis subgroups that can be defined prospec-
tively.
Currently. the trend in paediatric oncology is to avoid
radiotherapy wherever possible because of its side-effects on
growth. However. it is conceivable that children with slow-
responding T-cell lymphoblastic lymphoma mediastinal
masses could have their chance of long-term survival imp-
roved by local irradiation. A previous UKCCSG study in
which mediastinal radiotherapy showed a survival advantage
(Mott et al.. 1984) has been criticised because the
chemotherapy regimen used was considered suboptimal, and
it was suggested that the radiotherapy was compensating for
this inadequacy. Nevertheless, it emphasises that control of
mediastinal bulk disease is necessary for long-term survival
and that, in those patients who respond slowly and or par-
tially to more intensive drug regimens. mediastinal irradia-
tion could have a role. This view has been expressed by
others who have reported small studies but used mediastinal
radiotherapy for patients who presented with obstructive
symptoms and or responded slowly (Weinstein et al.. 1983:
Camitta et al.. 1985). One of the arguments against medias-
tinal irradiation has been the unnecessary exposure of the
70% or more patients who will be cured by chemotherapy
alone. Selection on the basis of initial response would avoid
its use in the majority of patients.
An alternative approach to try to improve the chance of
cure would be the use of more intensive chemotherapy at an
early stage. again using radiological speed of response as a
selection method. Exactly what this should comprise would
require careful consideration. as even in the 'poor-risk group
the survival is approximately 60%. Treatment with
significant early and late morbidity such as high-dose therapy
with marrow rescue or combining further anthracyclines and
mediastinal irradiation are unjustified without a worthwhile
gain in cure.
Clearly this retrospective analysis has limitations, as by
definition any data obtained in this way can only be safely
used to generate a hypothesis which then has to be tested
prospectively. To try to improve the discrimination using
speed of response of mediastinal disease in these patients. it
is planned to incorporate a series of carefully timed PA
CXRs into a future study. In addition. thoracic computerised
axial tomography will be performed. in order to try to imp-
rove the accuracy of assessing treatment response and to
evaluate the feasibility of guided fine-needle aspirates to look
for residual disease. The results will enable us to investigate
further the potential of this possible prognostic factor.
In conclusion, clinical and radiological parameters on all
78 stage III patients with confirmed T-cell lymphoblastic
lymphoma who were treated on UKCCSG study 8503 have
been collected and analysed retrospectively. A significant 5
year event-free and overall survival benefit have been demon-
strated for those patients whose mediastinal masses complete-
ly resolved by 60 days from the start of treatment using plain
PA CXR assessment. This simple measure of response to
chemotherapy may prove to be of use in modifying treatment
early on in patients who have persistent mediastinal abnor-
malities. in an attempt to improve the cure rate in this rare
paediatric malignancy.
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